Modification of bronchial hyperreactivity after treatment with sodium cromoglycate during pollen season

https://doi.org/10.1016/S0091-6749(85)80018-XGet rights and content

Repeated bronchial histamine challenges before, during, and after the birch pollen season were performed in 22 allergic patients with bronchial hyperreactivity (BHR) treated for 6 wk with sodium cromoglycate (SCG), 20 mg, four times a day, or placebo in a double-blind, randomized group comparison. Clinical assessments of the asthmatic symptom score and peak expiratory flow revealed less symptoms and less use of bronchodilators in the SCG group. Responsiveness to histamine was significantly increased in the placebo group after 14 days with high pollen counts. After the season there was an immediate return to preseasonal value. There was no change in responsiveness in the SCG group, demonstrating significant protection against pollen-induced increase of BHR. The results support the hypothesis that inhibition of mediator release, which is demonstrated for SCG, leads to a reduction of the nonspecific BHR.

References (35)

  • HegardtB et al.

    Histamine-induced bronchospasm. Its reproducibility and usage in clinical evaluation of the sub-threshold bronchodilating dose of a new beta-agonist KWD 2131

    Allergy

    (1980)
  • JuniperEF et al.

    Long-term stability of bronchial responsiveness to histamine

    Thorax

    (1982)
  • LöwhagenO et al.

    Short-term and long-term variation in bronchial response to histamine in asthmatic patients

    Eur J Respir Dis

    (1983)
  • AltounyanREC

    Changes in histamine and atropine responsiveness as a guide to diagnosis and evaluation of therapy in obstructive airway disease

  • LöwhagenO et al.

    Studies on histamine metabolism in allergen-induced asthma

    Allergy

    (1980)
  • KauffmanHF et al.

    Plasma histamine concentrations and complement activation during house dust mite-provoked bronchial obstructive reactions

    Clin Allergy

    (1983)
  • DicksonW

    A one year's trial of Intal compound on 24 children with severe asthma

  • Cited by (0)

    View full text